Atselizin

General characteristics. Structure:

1 bottle contains an atselizin sterile – 1 g

Main physical and chemical properties: crystal powder of inodorous white color or with a slight specific smell.

Pharmacological properties:

Pharmacodynamics. Atselizin is an injection form of acetylsalicylic acid and has properties, characteristic of it, and also increases its bioavailability and analgetic effect. Possesses analgeziruyushchy, antiinflammatory, febrifugal and anti-aggregation action.
Drug inhibits cyclooxygenase therefore synthesis of prostaglandins and formation of A2 thromboxane in thrombocytes is oppressed. Ability of thrombocytes and erythrocytes to pasting and sticking (adhesion) to an endothelium of blood vessels decreases. Reducing surface intention of membranes of erythrocytes, drug facilitates their deformation when passing through capillaries and improves a blood stream.

Pharmacokinetics. Drug contacts proteins of plasma for 80–90%. Gets into the majority of body tissues, including into synovial, cerebrospinal, peritoneal liquids. In blood it is hydrolyzed, forming acetylsalicylic acid and a lysine. In a liver acetylsalicylic acid turns into salicylic. The elimination half-life of acetylsalicylic acid makes 15–20 minutes, salicylic and its active metabolites of 3-6 o'clock (small doses) till 15-30 o'clock (high doses). It is excreted preferential by kidneys in not changed form (60%) and in the form of metabolites.

Indications to use:

Pain of different genesis: head, ear and tooth pains, mialgiya, neuralgia, arthralgias, pains in the postoperative period, as an antipyretic at feverish conditions of a different etiology, as anti-aggregation means for prevention of thromboses in cardiology and neurology, and also for prevention of disturbances of microcirculation.

Route of administration and doses:

To apply to destination and under control of the doctor.
Atselizin-KMP for injections enter intramusculary (deeply) and intravenously. For intramuscular introduction contents of a bottle are dissolved just before use: 1 g (1 bottle) – in 5 ml of water for injections, shaking up before full dissolution of powder.
For prevention of thrombosis the drug is administered intramusculary (deeply) on 0,5–3 ml of solution
1 time a day or in a day. A course of treatment – to 5 injections then if necessary it is possible to pass to reception of acetylsalicylic acid inside. The single dose and frequency of repeated injections of drug are defined by dynamics of data of laboratory inspection of indicators of a hemostasis after the first introduction Atselizina-KMP.
At intravenous administration Atselizina-KMP for prevention of thrombosis is preferred as slow injection of drug. Before use of 1 g (1 bottle) – dissolve in
5 ml of water for injections, shaking up before full dissolution of powder, the prepared solution enter on 150–200 ml 5% of solution of glucose or 0,9% of solution of sodium of chloride with a speed
1 ml/minute.
For decrease in body temperature at fever Atselizin-KMP enter intramusculary 1–2 g 1–3 times a day. As anesthetic Atselizin-KMP is entered intramusculary or intravenously on 1–2 g by 1–3 times a day. If necessary it is possible to increase a dose to 10–20 g intramusculary or intravenously in days.

To children: To children at the age of 4–6 years enter intramusculary (deeply) 10–25 mg/kg a day, from 6 to 10 years – on 0,25–0,5 g a day, 11 years – on 0,5–1 g a day, 1–2 times a day are more senior. The maximum daily dose for adults makes 20 g Atselizina-KMP. The course of treatment makes 3–10 days.

Features of use:

It is necessary to appoint with care at erosive and ulcer diseases of digestive tract in the anamnesis, bronchial asthma, a renal failure, gout, a menorrhagia, existence of an intrauterine contraceptive.

Side effects:

At use Atselizina-KMP are possible: gastrointestinal frustration (nausea, vomiting, dyspepsia), bleedings, a bronchospasm, bronchial asthma, an anaphylaxis, an exacerbation of gout, an aggravation of a peptic ulcer of a stomach and a 12-perstny gut, a metabolic alkalosis, dizziness, a headache, rash, a reversible hepatotoxic, a hypercalcemia, emergence of concrements in kidneys, hypostases, increase in arterial pressure.

Interaction with other medicines:

Reduces effect of antihypertensives; increases toxicity of a methotrexate, effects of narcotic analgetics (codeine, oxycodone, the propoxyhair dryer), heparin, indirect anticoagulants, trombolitik, inhibitors of aggregation of thrombocytes, peroral antidiabetic drugs. The risk of development of by-effects is increased by acetphenetidiene, antihistamines, acetaminophen, caffeine,
glucocorticoids – strengthen negative impact on a mucous membrane of digestive tract and increase clearance.

Overdose:

It is shown in the form of severe headaches, a sonitus, decrease in hearing, a febricula, fever. More serious poisoning – a stupor, spasms and a coma, not cardiogenic fluid lungs, severe dehydration, disturbance of acid-base equilibrium (in the beginning – a respiratory alkalosis, then – a metabolic acidosis).
Treatment: correction of acid-base equilibrium (infusion of solutions of sodium of bicarbonate, citrate, etc.). It is necessary to consider that intensive infusion of liquid for people of advanced age can lead to a fluid lungs. At the level of salicylates more than 5,55-7,22 mmol/l the hemodialysis is shown. At a fluid lungs – artificial ventilation of the lungs by the mix enriched with oxygen in the mode of positive pressure at the end of an exhalation; at wet brain – a hyperventilation and an osmotic diuresis.

Storage conditions:

To store in the dry, protected from light place at a temperature from 4 °C to 10 °C. A period of validity – 2 years. To store in the place, unavailable to children! Storage of ready solution is allowed no more than 30 minutes. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

On 1 g in bottles. 10 bottles in a pack.